Characteristics of and Mortality Associated With Diabetic Ketoacidosis Among US Patients Hospitalized With or Without COVID-19

• Type of Material: Article
• Authors: Francisco Pasquel, Emory University; Jordan Messler, Glytec, Inc, Waltham; Robert Booth, Glytec, Inc, Waltham; Beata Kubacka, Glytec, Inc, Waltham; April Mumpower, Glytec, Inc, Waltham; Guillermo Umpierrez, Emory University; Joseph Aloi, Wake Forest University
• Language: English
• Date: 2021-03-10
• Publisher: AMER MEDICAL ASSOC
• Publication Version: Final Published Version
• Copyright Statement: 2021 Pasquel FJ et al. JAMA Network Open.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1001/jamanetworkopen.2021.1091
• Title of Journal or Parent Work: JAMA NETWORK OPEN
• Volume: 4
• Issue: 3
• Start Page: e211091
• End Page: e211091
• Grant/Funding Information: Dr Pasquel is partially supported by the National Institutes of Health under award numbers 1K23GM128221-01A3 and P30DK111024-05S1.
• Keywords: Life Sciences & Biomedicine; Science & Technology; Medicine, General & Internal; General & Internal Medicine; TRENDS
• Research Categories: Health Sciences, Medicine and Surgery

Abstract

Diabetic ketoacidosis (DKA) is a life-threatening, acute complication of diabetes. Despite an increase in DKA hospitalization rates, the age-adjusted DKA in-hospital case-fatality rate has declined over time.1 However, with the advent of coronavirus disease 2019 (COVID-19), a suspected increase in the frequency and severity of DKA has been hypothesized because of the potential diabetogenic effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).2 To further characterize patients with DKA with and without COVID-19, we analyzed individual-level inpatient data from multiple US hospitals.